Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-30 11:50 am Sale | 2025-05-29 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 3,600,000 8.100% | -733,817 (-16.93%) | Filing History |
| 2025-05-15 4:10 pm Sale | 2025-03-31 | 13G | Harvard Bioscience, Inc. HBIO | HARVEY PARTNERS, LLC | 2,187,500 4.960% | -370,000 (-14.47%) | Filing History |
| 2025-05-14 12:28 pm Purchase | 2025-05-13 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 4,333,817 9.800% | 563,465 (+14.94%) | Filing History |
| 2025-05-08 12:45 pm Purchase | 2025-03-31 | 13G | Harvard Bioscience, Inc. HBIO | Weber Capital Management, LLC | 3,200,380 7.260% | 683,450 (+27.15%) | Filing History |
| 2025-04-08 09:49 am Purchase | 2025-04-01 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 3,770,352 8.600% | 485,817 (+14.79%) | Filing History |
| 2025-04-07 4:06 pm Sale | 2025-03-31 | 13G | Harvard Bioscience, Inc. HBIO | Punch & Associates Investment Management, Inc. | 25,586 0.100% | -2,892,448 (-99.12%) | Filing History |
| 2025-03-17 10:33 am Purchase | 2025-03-14 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 3,284,535 7.500% | 1,139,644 (+53.13%) | Filing History |
| 2025-02-10 4:56 pm Purchase | 2024-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Weber Capital Management, LLC | 2,516,930 5.770% | 2,516,930 (New Position) | Filing History |
| 2025-02-04 10:37 am Sale | 2025-02-03 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,144,891 4.900% | -163,731 (-7.09%) | Filing History |
| 2024-11-14 12:31 pm Sale | 2024-09-30 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 1,555,820 3.600% | -1,383,458 (-47.07%) | Filing History |
| 2024-03-19 1:02 pm Purchase | 2024-03-18 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,308,622 5.320% | 201,952 (+9.59%) | Filing History |
| 2024-02-14 4:05 pm Sale | 2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO | HARVEY PARTNERS, LLC | 2,557,500 6.000% | -354,000 (-12.16%) | Filing History |
| 2024-02-14 09:00 am Purchase | 2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Punch & Associates Investment Management, Inc. | 2,918,034 6.800% | 153,995 (+5.57%) | Filing History |
| 2024-02-14 08:46 am Sale | 2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 2,939,278 6.900% | -325,518 (-9.97%) | Filing History |
| 2024-02-13 4:01 pm Sale | 2024-01-09 | 13G | HARVARD APPARATUS REGENERATIVE HRGN | HARVARD BIOSCIENCE INC HBIO | 697,112 5.000% | -11,404 (-1.61%) | Filing History |
| 2024-01-26 5:26 pm Purchase | 2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO | BlackRock Inc. BLK | 2,913,814 6.800% | 1,704,695 (+140.99%) | Filing History |
| 2024-01-22 10:55 am Sale | 2024-01-16 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,106,670 4.940% | -52,124 (-2.41%) | Filing History |
| 2023-08-28 3:07 pm Purchase | 2023-08-25 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,158,794 5.060% | 104,887 (+5.11%) | Filing History |
| 2023-02-16 3:11 pm Unchanged | 2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 3,264,796 7.800% | 0 (Unchanged) | Filing History |
| 2023-02-15 5:30 pm Purchase | 2022-11-29 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 3,264,796 7.840% | 3,264,796 (New Position) | Filing History |